Pacer Advisors Inc. Buys 680,818 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Pacer Advisors Inc. lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4,020.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 697,753 shares of the medical equipment provider’s stock after buying an additional 680,818 shares during the quarter. Pacer Advisors Inc.’s holdings in Zimmer Biomet were worth $62,742,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of ZBH. Dodge & Cox boosted its holdings in shares of Zimmer Biomet by 1.3% during the fourth quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock worth $2,113,736,000 after acquiring an additional 290,676 shares during the period. Vanguard Group Inc. increased its stake in shares of Zimmer Biomet by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock worth $2,111,658,000 after purchasing an additional 192,517 shares during the period. State Street Corp lifted its holdings in Zimmer Biomet by 2.3% during the 4th quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock worth $795,814,000 after purchasing an additional 195,214 shares during the last quarter. Capital International Investors lifted its holdings in Zimmer Biomet by 11.5% during the 3rd quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after purchasing an additional 778,467 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in Zimmer Biomet by 43.2% in the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after purchasing an additional 2,017,857 shares during the period. Institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.28% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $88.13 on Friday. The firm has a 50 day moving average of $87.34 and a 200-day moving average of $90.15. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $17.05 billion, a PE ratio of 22.89, a PEG ratio of 2.56 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.23. The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter last year, the business posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.49 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 24.94%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ZBH. Canaccord Genuity Group set a $83.00 price objective on Zimmer Biomet in a research report on Wednesday, April 29th. William Blair began coverage on shares of Zimmer Biomet in a research report on Friday, February 20th. They issued a “market perform” rating for the company. Weiss Ratings upgraded shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. BTIG Research reaffirmed a “neutral” rating on shares of Zimmer Biomet in a research report on Monday, March 23rd. Finally, JPMorgan Chase & Co. cut their price objective on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $102.70.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.